Education
About Us
Working with TipRanks
Follow Us
Biosyent Inc (TSE:RX)
:RX
Earnings Data
Report Date
May 23, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.15Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: 1.85%
|Next Earnings Date:May 23, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with record revenue and consistent profitability. The company demonstrated effective capital allocation through dividends and share buybacks, and showcased growth potential with the Tibelia acquisition and new product developments. However, there were challenges with the legacy business and international segment, along with geopolitical uncertainties. Overall, the positive aspects significantly outweighed the negatives.Company Guidance
In the Q4 and Fiscal Year 2024 results presentation, BioSyent Inc. showcased robust financial performance with a record quarterly revenue of just under $8.8 million, driven by Canadian and international pharma sales. The company's EBITDA surged by 36% compared to the previous year, with margins improving from 20% to 25%. For the full fiscal year, revenue exceeded $35 million, marking a double-digit increase, while net income after tax reached nearly $7.3 million, reflecting a 13% growth and maintaining an 18% NIAT margin. The company's earnings per share rose by 17% to $0.62 for the year. BioSyent also highlighted its strategic moves, including the acquisition of Tibelia Global, contributing to future growth, alongside consistent shareholder returns through dividends and share buybacks. Despite geopolitical uncertainties, the company remains confident in its strong start to 2025 and its ability to sustain revenue and profit growth.Record Quarterly Revenue
The company achieved record sales of just under $8.8 million in the fourth quarter, driven by Canadian and international pharma segments.
Significant EBITDA Growth
EBITDA increased by 36% in the quarter, with the margin growing from 20% to 25% compared to the previous year.
Consistent Profitability
The company reported its 58th consecutive profitable quarter, with earnings per share growth of 17% year-over-year.
TSX Venture Recognition
BioSyent was named one of the top 50 performing TSX Venture companies in 2024, reflecting strong performance in price, volume, and value.
Dividend and Share Buybacks
The quarterly dividend was increased by 11%, and over 492,000 shares were repurchased in 2024.
Tibelia Global Acquisition
The acquisition began contributing to revenue in early 2025, with shipments totaling CAD800,000 in January and February.
New Product Developments
The company is preparing a new endocrinology product for a 2026 launch, expected to significantly contribute to revenue.
---
TSE:RX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:RX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | C$10.80 | C$11.20 | +3.70% |
| Nov 20, 2024 | C$10.82 | C$11.20 | +3.51% |
| Aug 26, 2024 | C$10.08 | C$10.47 | +3.87% |
| May 16, 2024 | C$8.35 | C$8.84 | +5.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biosyent Inc (TSE:RX) report earnings?
Biosyent Inc (TSE:RX) is schdueled to report earning on May 23, 2025, TBA Not Confirmed.
What is Biosyent Inc (TSE:RX) earnings time?
Biosyent Inc (TSE:RX) earnings time is at May 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:RX EPS forecast?
Currently, no data Available
---